Blood test may take the guesswork out of transplant drug dosing

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects received a kidney transplant in the prior 3 months. * Subjects receiving maintenance therapy consisting of tacrolimus, mycophenolate sodium or mycophenolate mofetil, and optionally corticosteroids, at the time of enrollment. * Subjects received induction therapy comprising IL2 receptor antagonist or thymoglobulin, or received no induction therapy. * 18 years of age or older at time of signing informed consent. * Able to read, understand and provide written informed consent, and willing and able to comply with the study requirements. If the subject is unable to sign the informed consent, a legally authorized representative (LAR) can consent on behalf of the subject. * Subjects are at the site standard-of-care MPA dosage Exclusion Criteria: * Concurrent multiple solid organ or tissue transplants. * History of a previous organ transplant (aside from present kidney transplant), or cellular transplant. * DSA Positive according to local protocol, including either pre-transplant DSA positivity and de novo DSA positivity. * Any prior dd-cfDNA results ≥1.0% or ≥78cp/mL after 28 days post-transplant. * ABO Incompatible donor. * A serious medical condition that may adversely affect ability to participate in the study (e.g, current diagnosis of cancer). * Pregnancy. * Received any induction therapy other than IL2 receptor antagonist or thymoglobulin. * Receiving any maintenance immunosuppression other than tacrolimus, mycophenolate sodium or mycophenolate mofetil, and prednisone. * Currently undergoing regular dialysis. * Considered high-risk at the time of enrollment, as per the treating physician. * Planned or ongoing use of other commercially available or investigational dd-cfDNA or blood-based gene expression profile assays for rejection surveillance, through randomization.